现代妇产科进展Issue(10)：787-789,3.DOI:10.13283/j.cnki.xdfckjz.2014.10.008
sTWEAK在上皮性卵巢癌患者血清中的表达及其意义
Serum sTWEAK expression and its clinical significance in epithelial ovarian cancer pa-tients
黄毓丽 1邱丽华2
作者信息
- 1. 上海交通大学医学院附属仁济医院妇产科，上海 200127
- 2. 上海交通大学医学院附属新华医院崇明分院妇产科，上海 202150
- 折叠
摘要
Abstract
Objective:To explore the expression level and clinical implications of ser-um soluble tumor necrosis factor---like weak inducer of apoptosis( sTWEAK) in epithelial o-varian cancer patients. Method:20 patients with epithelial ovarian cancer ( EOC group) and 23 patients with benign epithelial ovarian tumor ( BOT group) were selected from Renji Hospital, School of Medicine,Shanghai Jiaotong University. These patients were admitted to the hospital during the period from Jan. 2010 to Feb. 2014. The levels of serum sTWEAK were detected by ELISA. Results:(1) Compared to the BOT group,the expression levels of sTWEAK were sig-nificantly increased in the EOC group (P<0. 05). In both groups,the expression levels of sTWEAK were positively correlated with serum CA125 levels ( r=0 . 42 , P<0 . 05 ) . Further-more,compared to patients with a CA125>500U/ml,the expression levels of sTWEAK were sig-nificantly decreased in patients with a CA125<500 U/ml ( P<0 . 05 ) . In peripheral serum of the EOC group,the expression levels of sTWEAK were not correlated to clinical stages,histological grade,pathological types and ascites presence of tumor cells(P>0. 05). (3)In EOC group,the proportion of optimal primary cytoreduction in patients with a CA125<500 U/ml is significantly higher than that in patients with a CA125>500 U/ml ( P<0 . 05 ) . Conclusions:Serum sTWEAK levels were closely correlated with the pathogenesis of EOC. sTWEAK might be used as a new serum marker for diagnosis and prognosis in EOC.关键词
上皮性卵巢癌/sTWEAK/CA125Key words
Epithelial ovarian cancer/sTWEAK/CA125分类
医药卫生引用本文复制引用
黄毓丽,邱丽华..sTWEAK在上皮性卵巢癌患者血清中的表达及其意义[J].现代妇产科进展,2014,(10):787-789,3.
